Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX in Second-Line Irresectable Cholangiocarcinoma
NCT02456714Phase 2Completed
- Sponsor
- University of Amsterdam
- Start
- May 2016
- Primary completion
- Oct 2018
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FOLFIRINOX in cholangiocarcinoma (CCA), sponsored by University of Amsterdam. Primary endpoints: Toxicity at 24 weeks and Response Rate at 24 weeks. Started May 2016; status: completed.
02
Drugs
FOLFIRINOX
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02456714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02456714.